Nicht aus der Schweiz? Besuchen Sie lehmanns.de

PEGylated Protein Drugs: Basic Science and Clinical Applications

Francesco M. Veronese (Herausgeber)

Buch | Hardcover
IX, 290 Seiten
2009 | 2009
Springer Basel (Verlag)
978-3-7643-8678-8 (ISBN)
CHF 299,55 inkl. MwSt
This topical volume introduces PEGylation technology and key applications. Basic physical and chemical properties of PEG are discussed. The competent authorship from academia and industry assures comprehensive information.

PEGylation technology and key applications are introduced by this topical volume. Basic physical and chemical properties of PEG as basis for altering/improving in vivo behaviour of PEG-conjugates such as increased stability, improved PK/PD, and decreased immunogenicity, are discussed. Furthermore, chemical and enzymatic strategies for the coupling and the conjugate characterization are reported. Following chapters describe approved and marketed PEG-proteins and PEG-oligonucleotides as well as conjugates in various stages of clinical development.

Preface PEGylated protein conjugates: A new class of therapeutics for the 21st century.- Protein PEGylation, basic science and biological applications.- Reactive PEGs for protein conjugation.- Rebridging disulphides: site-specific PEGylation by sequential bis-alkylation.- Enzymatic techniques for PEGylation of biopharmaceuticals.- The site-specific TGase-mediated PEGylation of proteins occurs at flexible sites.- Protein conjugates purification and characterization.- PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals.- The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol).- Pegfilgrastim - designing an improved form of rmetHuG-CSF.- PEGylation of human growth hormone: strategies and properties.- PEGylated ? interferons: two different strategies to achieve increased efficacy.- Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout.- Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent.- PEG: a useful technology in anticancer therapy.- Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines.

From the reviews:

"The volume is dedicated to the recent advances on PEGylation and PEGylated compunds. It represents an excellent update in the evolution of this field, from nanoscience to clinical applications. The book provides an excellent update in this rapidly evolving field. ... This valuable volume which will spark the interest of both researchers and clinicians contributes to a better understanding of polymer therapeutics." (Magdalena Moisei, Romanian Journal of Biochemistry, Vol. 47 (2), 2010)

Erscheint lt. Verlag 18.9.2009
Reihe/Serie Milestones in Drug Therapy
Zusatzinfo IX, 290 p.
Verlagsort Basel
Sprache englisch
Maße 170 x 244 mm
Gewicht 596 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Pharmazie
Schlagworte biopharmaceuticals • Cancer • Cancer Therapy • Certolizumab pegol • Erythropoietin • Interferon • necrosis • Nucleotide • Pegfilgrastim • PEG Preparation • PEGylation technique • Pharmaceutical • Preparation • Protein • Protein conjugation • Protein / Eiweiß • proteins • Research • Toxicity
ISBN-10 3-7643-8678-9 / 3764386789
ISBN-13 978-3-7643-8678-8 / 9783764386788
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich